BREAKING NEWS
GMP Manufacturing
Has Completed!
We are very pleased to announce an important milestone - GMP manufacturing has finished at our CDMO STC Biologics Inc for CPI-601 our recombinant enzyme replacement therapy for Batten Disease CLN1. Analytical testing is ongoing and then we have drug product filling. The next stage is a clinical trial.
There is currently no FDA approved treatment for this ultra-rare fatal disease. CPI-601 development has been funded by the National Institute of Neurological Disorders and Stroke (NINDS). If you are interested in partnering with us please get in touch.
View Pipeline
OUR MISSION
Transforming Chemistry,
Enriching Lives
We use real drug discovery intelligence alongside artificial intelligence to develop clinical candidates for rare, neglected and unmet therapeutic needs.
Our pipeline reflects years of dedicated research, innovative breakthroughs, and a commitment to bringing life-changing treatments to those who need them most.
View Pipeline
OUR TOOLS
Innovative Solutions To Complex Challenges
Whether you’re looking to predict toxicity, visualize molecular data, or build machine learning models, our tools are designed to meet your unique needs.
Not sure which tool is right for you?
Take our short assessment to find the perfect solution for your professional goals.
OUR PARTNER
Drive Success Through Collaboration
Breakthroughs happen when expertise meets opportunity. At the core of our success lies a commitment to collaboration, partnering with innovators, organizations, and researchers who share our vision for advancing science and transforming lives.
Whether through licensing agreements, strategic partnerships, or tailored contracting solutions, we build relationships that deliver meaningful impact.
Partner With UsWHO WE ARE
Innovators in Machine Learning and ADME/Tox
Collaborations Pharmaceuticals, Inc.® is a privately owned company that performs research and development on innovative therapeutics for multiple rare and neglected infectious diseases. We develop and apply our artificial intelligence (AI) software to aid in drug discovery and toxicology assessment as well as to identify and translate early preclinical to clinical stage assets. Our software can also be used to design new molecules with desired properties. This software can be used by pharmaceutical, consumer product, as well as other companies that require chemistry.
>150
9
3
2
12
7
WHAT WE DO
No Disease Is Too Small
We apply our machine learning and drug discovery expertise to a wide array of projects both internally and with collaborators. Our toxicology models and read across software could assist your companies sustainable chemistry goals and help you in regulatory filings. We have developed new approaches which can be used to rapidly predict molecular properties for massive DNA-encoded libraries or predict properties for PROTACS. In the process of our work we have raised awareness of the potential for dual use of these AI technologies and therefore have expertise for such evaluations which has caught the attention of government agencies.
FEATURED PUBLICATION
Inhibition of equilibrative nucleoside transporters 1 and 2 by proteolysis-targeting chimeras (PROTACs)
Patricia A Vignaux, Lucy J Martinez Guerrero, Renuka Raman, Thomas R Lane, Javier Perez, Dominique O Farrera, Stephen H Wright, Nathan J Cherrington, Sean Ekins. 2025 Dec; DOI: 10.1016/j.jpet.2025.103635
Proteolysis-targeting chimeras (PROTACs) are gathering considerable interest due to their ability to address previously undruggable targets. We were keen to understand the potential for these very large molecules to interact with transporters that may influence absorption, distribution, metabolism, and excretion or toxicity properties and to what extent this may be predictable using machine learning models. Consequently, we tested a set of PROTACs against several human drug transporters, namely the equilibrative nucleoside (ENT) family transporters ENT1 and ENT2, which have been directly implicated in the uptake of anticancer or antiviral drugs into target cells. [...]
READ MOREMachine Learning & Generative Design Tools
SEE ALL TOOLS
A platform for the generative design of molecules to create new intellectual property
SEE DETAILS
A suite of tools to curate structure activity data, then build and validate machine learning models
SEE DETAILS
Thousands of machine learning models to help prioritize new uses and off target effects of molecules
SEE DETAILS
A suite of ADME and toxicology machine learning models with optional read across module
SEE DETAILS
Human uptake and efflux transporter machine learning models
SEE DETAILS
Molecule preparation, autocuration and data visualization tools
SEE DETAILS
Acetylcholinesterase machine learning models for multiple species
SEE DETAILS
A comprehensive database of macrolactones and associated biological data
SEE DETAILS
Prediction of the UV-VIS spectra for a molecule from structure alone
SEE DETAILS
A robust chemical inventory tracking software with fine-grained location tracking, advanced querying options, and cross-platform support.
SEE DETAILSHOW WE’RE DIFFERENT
Scientists Focused On Doing Science
Collaborations Pharmaceuticals, Inc.® is a privately owned company that performs research and development. We can apply our artificial intelligence (AI) software to aid your company in solving challenges you may encounter. Our software can be used by pharmaceutical, agrochemical, consumer product companies and anyone interested in chemistry.
CONTACT US